<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC, AND HYDROCORTISONE- neomycin sulfate, polymyxin b sulfate, bacitracin zinc and hydrocortisone ointment </strong><br>Akorn, Inc.<br></p></div>
<h1>Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment, USP
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:
</h1>
<p class="First">Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment, USP is a sterile antimicrobial and anti-inflammatory ointment for ophthalmic use. The color of the product is colorless to light yellowish.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-2.1"></a><p></p>
<h2>Each Gram Contains:
</h2>
<p class="First"><span class="Bold">ACTIVES:</span> Neomycin Sulfate equivalent to 3.5 mg neomycin base, Polymyxin B Sulfate equal to 10,000 polymyxin B units, Bacitracin Zinc equivalent to 400 bacitracin units, and Hydrocortisone 10 mg (1%);
</p>
<p><span class="Bold">INACTIVE:</span> White Petrolatum q.s.
</p>
<p>Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of <span class="Italics">Streptomyces fradiae</span> Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 mcg of neomycin standard per mg, calculated on an anhydrous basis. The structural formulae are:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Neomycin Sulfate Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce7ded34-66ab-4b6d-a9d7-fcf0c8d86eaa&amp;name=neo03-0001-01.jpg">
</div>
<p>Polymyxin B sulfate is the sulfate salt of polymyxin B<span class="Sub">1</span> and B<span class="Sub">2</span> which are produced by the growth of <span class="Italics">Bacillus polymyxa</span> {Prazmowski} Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are:
</p>
<div class="Figure">
<a name="f02"></a><img alt="Polymyxin B Sulfate Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce7ded34-66ab-4b6d-a9d7-fcf0c8d86eaa&amp;name=neo03-0001-02.jpg">
</div>
<p>Bacitracin zinc is the zinc salt of bacitracin, a mixture of related cyclic polypeptides (mainly bacitracin A) produced by the growth of an organism of the <span class="Italics">licheniformis</span> group of <span class="Italics">Bacillus subtilis</span> var Tracy. It has a potency of not less then 40 bacitracin units per mg. The structural formula is:
</p>
<div class="Figure">
<a name="f03"></a><img alt="Bacitracin Zinc Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce7ded34-66ab-4b6d-a9d7-fcf0c8d86eaa&amp;name=neo03-0001-03.jpg">
</div>
<p>Hydrocortisone, 11β 17, 21-trihydroxypregn-4-ene-3, 20-dione, is an anti-inflammatory hormone. The structural formula is:
</p>
<div class="Figure">
<a name="f04"></a><img alt="Hydrocortisone Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce7ded34-66ab-4b6d-a9d7-fcf0c8d86eaa&amp;name=neo03-0001-04.jpg">
</div>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s4"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:
</h1>
<p class="First">Corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticosteroids may inhibit the body's defense mechanism against <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.
</p>
<p>When a decision to administer both a corticosteroid and antimicrobials is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of all drugs is administered. When each type of drug is in the same formulation, compatibility of ingredients is assured and the correct volume of drug is delivered and retained.
</p>
<p>The relative potency of corticosteroids depends on the molecular structure, concentration and release from the vehicle.
</p>
<div class="Section" data-sectionCode="49489-8">
<a name="s5"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold">Microbiology:</span> The anti-infective components in Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment, USP are included to provide action against specific organisms susceptible to it. Neomycin sulfate and polymyxin B sulfate are active <span class="Italics">in vitro</span> against susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms: <span class="Italics">Staphylococcus aureus</span>, streptococci, including <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Escherichia coli</span>, <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Klebsiella/ Enterobacter species</span>, <span class="Italics">Neisseria species</span>, and <span class="Italics">Pseudomonas aeruginosa</span>. This product does not provide adequate coverage against Serratia marcescens (see <span class="Bold"><a href="#s6">INDICATIONS AND USAGE</a></span>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s6"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE:
</h1>
<p class="First">Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a risk of <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> exists.
</p>
<p>Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. They are also indicated in chronic <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">anterior uveitis</span> and corneal injury from chemical, radiation, or <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">thermal burns</span>, or penetration of foreign bodies.
</p>
<p>The use of a combination drug with an anti-infective component is indicated where the risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see <span class="Bold"><a href="#s5">CLINICAL PHARMACOLOGY: Microbiology</a></span>).
</p>
<p>The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: <span class="Italics">Staphylococcus aureus</span>, streptococci, including <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Escherichia coli</span>, <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Klebsiella/Enterobacter species</span>, <span class="Italics">Neisseria species</span>, and <span class="Italics">Pseudomonas aeruginosa</span>.
</p>
<p>The product does not provide adequate coverage against <span class="Italics">Serratia marcescens</span>.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s7"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS:
</h1>
<p class="First">Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment is contraindicated in most viral diseases of the cornea and conjunctiva including: epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span> (<span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">dendritic keratitis</span>), <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span> and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and also in <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infection</span> of the eye and fungal diseases of ocular structures.
</p>
<p>Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment is also contraindicated in individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to the antibiotic component occurs at a higher rate than for other components.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s8"></a><a name="section-6"></a><p></p>
<h1>WARNINGS:
</h1>
<p class="First">NOT FOR INJECTION INTO THE EYE. Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment should never be directly introduced into the anterior chamber of the eye. Ophthalmic ointments may retard corneal <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.
</p>
<p>Prolonged use of corticosteroids may result in <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> and/or <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, with damage to the optic nerve, defects in visual acuity and fields of vision, and in <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation.
</p>
<p>Prolonged use may suppress the host immune response and thus increase the hazard of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and <span class="product-label-link" type="condition" conceptid="4088088" conceptname="Scleral thinning">scleral thinning</span>. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation.
</p>
<p>Acute purulent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the eye may be masked or enhanced by the presence of corticosteroid medication.
</p>
<p>If these products are used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in uncooperative patients. Corticosteroids should be used with caution in the presence of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Intraocular pressure should be checked frequently.
</p>
<p>The use of corticosteroids after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery may delay healing and increase the incidence of filtering blebs.
</p>
<p>Use of the ocular corticosteroids may prolong the course and may exacerbate the severity of many <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the eye (including herpes simplex). Employment of corticosteroid medication in the treatment of herpes simplex requires great caution; frequent slit lamp microscopy is recommended.
</p>
<p>Topical antibiotics, particularly neomycin sulfate, may cause cutaneous sensitization. A precise incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (primarily <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>) due to topical antibiotics is not known. The manifestations of sensitization to topical antibiotics are usually <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, reddening, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the conjunctiva and eyelid. A sensitization reaction may manifest simply as a failure to heal. During long-term use of topical antibiotic products, periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. Symptoms usually subside quickly on withdrawing the medication. Applications of products containing these ingredients should be avoided for the patient thereafter (see <span class="Bold"><a href="#s10">PRECAUTIONS: General</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s9"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s10"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">General:</span> The initial prescription and renewal of the medication order beyond 8 grams should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after two days, the patient should be re-evaluated.
</p>
<p>As <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> of the cornea are particularly prone to develop coincidentally with long-term corticosteroid applications, fungal invasion should be suspected in any persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate.
</p>
<p>If this product is used for 10 days or longer, intraocular pressure should be monitored (see <span class="Bold"><a href="#s8">WARNINGS</a></span>).
</p>
<p>There have been reports of bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> associated with the use of topical ophthalmic products in multiple-dose containers which have been inadvertently contaminated by patients, most of whom had a concurrent corneal disease or a disruption of the ocular, epithelial surface (see <span class="Bold"><a href="#s11">PRECAUTIONS: Information for Patients</a></span>).
</p>
<p>Allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>; kanamycin, paromomycin, streptomycin, and possibly gentamicin.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s11"></a><a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold">Information for Patients:</span> If <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> persists longer than 48 hours or becomes aggravated, the patient should be advised to discontinue use of the medication and consult a physician.
</p>
<p>This product is sterile when packaged. To prevent contamination, care should be taken to avoid touching the tip of the tube to eyelids or to any other surface. The use of this tube by more than one person may spread <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Store between 20° to 25°C (68° to 77°F). Keep out of reach of children.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s12"></a><a name="section-7.3"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span> Long-term studies in animals to evaluate carcinogenic or mutagenic potential have not been conducted with polymyxin B sulfate or bacitracin. Treatment of cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> in vitro with neomycin increased the frequency of chromosome aberrations at the highest concentrations (80 mcg/mL) tested; however, the effects of neomycin on carcinogenesis and mutagenesis in humans are unknown.
</p>
<p>Long-term studies in animals (rats, rabbits, mice) showed no evidence of carcinogenicity or mutagenicity attributable to oral administration of corticosteroids. Long-term animal studies have not been performed to evaluate the carcinogenic potential of topical cor-ticosteroids. Studies to determine mutagenicity with hydrocortisone have revealed negative results.
</p>
<p>Polymyxin B has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown. No adverse effects on male or female fertility, litter size or survival were observed in rabbits given bacitracin zinc 100 gm/ton of diet. Long-term animal studies have not been performed to evaluate the effect on fertility of topical corticosteroids.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s13"></a><a name="section-7.4"></a><p></p>
<p class="First"><span class="Bold">Pregnancy:
</span><span class="Bold Italics">Teratogenic Effects</span>: Pregnancy Category C. Corticosteroids have been found to be teratogenic in rabbits when applied topically at concentrations of 0.5% on days 6 to 18 of gestation and in mice when applied topically at a concentration of 15% on days 10 to 13 of gestation. There are no adequate and well-controlled studies in pregnant women. Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s14"></a><a name="section-7.5"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span> It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s15"></a><a name="section-7.6"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span> Safety and effectiveness in pediatric patients have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s16"></a><a name="section-7.7"></a><p></p>
<p class="First"><span class="Bold">Geriatric Use:</span> No overall differences in safety or effectiveness have been observed in between elderly and younger patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s17"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS:
</h1>
<p class="First">Adverse reactions have occurred with corticosteroid/anti-infective combination drugs which can be attributed to the corticosteroid component, the anti-infective component, or the combination. The exact incidence is not known.
</p>
<p>Reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitization reactions including <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and conjunctival <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (see <span class="Bold"><a href="#s8">WARNINGS</a></span>). More serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have been reported rarely.
</p>
<p>The reactions due to the corticosteroid component in decreasing order of frequency are: elevation of intra-ocular pressure (IOP) with possible development of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, and infrequent optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>; <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation; and delayed <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="e17"></a><a name="section-8.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">Secondary Infection</span>:</span> The development of the <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span> has occurred after use of combinations containing corticosteroids and antimicrobials. Fungal and <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the cornea are particularly prone to develop with long-term applications of a corticosteroid. The possibility of fungal invasion must be considered in any persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> where corticosteroid treatment has been used (See <span class="Bold"><a href="#s8">WARNINGS</a></span>).
</p>
<p>Local irritation on instillation has also been reported.
</p>
<p>If signs and symptoms fail to improve after two days, the patient should be re-evaluated (see <span class="Bold"><a href="#s9">PRECAUTIONS</a></span>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s18"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:
</h1>
<p class="First">Apply the ointment in the affected eye every 3 or 4 hours, depending on the severity of the condition.
</p>
<p>Not more than 8 grams should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in <span class="Bold"><a href="#s9">PRECAUTIONS</a></span> above.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s19"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED:
</h1>
<p class="First">Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment, USP is supplied in a tube with ophthalmic applicator tip in the following size:
</p>
<dl>
<dt> 
</dt>
<dd>NDC 17478-719-35           1/8 oz (3.5 g) tube
</dd>
</dl>
<table width="100%">
<col width="100.000%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><span class="Bold">DO NOT USE IF BOTTOM RIDGE OF TUBE CAP IS EXPOSED.</span></td></tr></tbody>
</table>
<p><span class="Bold">FOR OPHTHALMIC USE ONLY.</span></p>
<div class="Section" data-sectionCode="44425-7">
<a name="e19"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span> Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
</p>
<p><span class="Bold">KEEP OUT OF REACH OF CHILDREN</span></p>
<p><span class="Bold">Akorn</span></p>
<p>Manufactured by: <span class="Bold">Akorn Inc.<br></span>Lake Forest, IL 60045<br>NP00N<br>Revision 10/11
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s20"></a><a name="section-11"></a><p></p>
<p class="First">Principal Display Panel Text for Container Label:
</p>
<p>NDC 17478-719-35 Akorn Logo
</p>
<p>Neomycin and Polymyxin B Sulfates,
</p>
<p>Bacitracin Zinc, and Hydrocortisone Ophthalmic
</p>
<p>Ointment, USP
</p>
<p>STERILE OPHTHALMIC OINTMENT Net Wt. 3.5 g (1/8 oz)
</p>
<p>Rx only
</p>
<div class="Figure">
<a name="f05"></a><img alt="Principal Display Panel Text for Container Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce7ded34-66ab-4b6d-a9d7-fcf0c8d86eaa&amp;name=neo03-0001-05.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s21"></a><a name="section-12"></a><p></p>
<p class="First">Principal Display Panel Text for Carton Label:
</p>
<p>NDC 17478-719-35
</p>
<p>Neomycin and Polymyxin B Sulfates,
</p>
<p>Bacitracin Zinc, and Hydrocortisone
</p>
<p>Ophthalmic Ointment, USP
</p>
<p>Sterile Ophthalmic Ointment
</p>
<p> Rx only        Net Wt. 3.5 g (1/8 oz) Akorn Logo
</p>
<div class="Figure">
<a name="f06"></a><img alt="Principal Display Panel Text for Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce7ded34-66ab-4b6d-a9d7-fcf0c8d86eaa&amp;name=neo03-0001-06.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC, AND HYDROCORTISONE 		
					</strong><br><span class="contentTableReg">neomycin sulfate, polymyxin b sulfate, bacitracin zinc, hydrocortisone ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17478-719</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Neomycin Sulfate</strong> (neomycin) </td>
<td class="formItem">neomycin</td>
<td class="formItem">3.5 mg  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Polymyxin B Sulfate</strong> (Polymyxin B) </td>
<td class="formItem">Polymyxin B</td>
<td class="formItem">10000 [USP'U]  in 1 g</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Bacitracin Zinc</strong> (bacitracin) </td>
<td class="formItem">bacitracin</td>
<td class="formItem">400 [USP'U]  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Hydrocortisone</strong> (Hydrocortisone) </td>
<td class="formItem">Hydrocortisone</td>
<td class="formItem">10 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Petrolatum</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-719-35</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3.5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065213</td>
<td class="formItem">07/25/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Akorn, Inc.
							(062649876)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Akorn, Inc. </td>
<td class="formItem"></td>
<td class="formItem">603980319</td>
<td class="formItem">MANUFACTURE(17478-719), ANALYSIS(17478-719), STERILIZE(17478-719), LABEL(17478-719), PACK(17478-719)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>60ddae47-eb84-455b-af3f-6bf4e3d114bc</div>
<div>Set id: ce7ded34-66ab-4b6d-a9d7-fcf0c8d86eaa</div>
<div>Version: 1</div>
<div>Effective Time: 20120727</div>
</div>
</div> <div class="DistributorName">Akorn, Inc.</div></p>
</body></html>
